This year’s World Heart Day is centered around the theme of ‘Cardiovascular Health for Everyone,’ which raises awareness of the prevention, treatment and management of cardiovascular disease worldwide. At Jazz, we know that people living with sleep disorders, such as narcolepsy, face risks in developing some of these comorbidities, and we are committed to exploring solutions that can help effectively manage the impacts they face, including hypertension, cardiovascular disease, obesity and diabetes.
In honor of Blood Cancer Awareness Month, Abizer Gaslightwala Vice President, Head of US Hematology/Oncology Business Unit at Jazz, reflects on Jazz’s commitment to patients with blood cancer and the unique partnership with a childhood cancer research group that enabled the accelerated development process of a new treatment option for some blood cancer patients to ensure reliable access to treatment without obstacles to their care.
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.
You are now leaving www.JazzPharma.com. Thank you for visiting. The information on the website you are entering is intended for visitors in the United States only.
